Abstract 525P
Background
Glioblastoma (GBM) is characterized by an “immune-deserted” tumor microenvironment (TME) consisting of tumor-associated macrophages (TAMs) and tumor infiltrating lymphocytes (TILs). We aimed to investigate the prognostic role of tumor tissue markers correlating with overall survival (OS) and progression-free survival (PFS).
Methods
By immunohistochemistry (IHC), we analyzed on 31 archival formalin-fixed paraffin embedded (FFPE) tissue specimens: CD3, CD4, CD8, CD20, CD45, CD68, CD163, CD66b and PDL-1. Expression values were classified according to density score from 0 to 4 (0=no expression; 1=1-25%; 2=26-50%, 3=51-74%; 4=75%-100%) in two areas: Vascular/perivascular (V) and diffuse in tumor parenchyma (D). Percentage of infiltrating immune system cell was calculated by the rate of absolute number of positive stained cells/total number of cells multiplied by 100.
Results
All tissues were negative for PDL1 and only two positive for CD20. We observed that CD68+ macrophage and CD66b+ neutrophils expressed in V showed a statistically significant prognostic role (p-value of 0.027 and 0.029 respectively) (Table). CD68-V showed a prognostic role for PFS (p-value 0.032), while CD66b-V expression did not. CD3, CD4, CD8, CD45 and CD163 were not associated with OS and PFS.
Table: 525P
Characteristics | Univariable models OS | Multivarible model OS | Univariable models PFS | Multivarible model PFS | ||||
HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | |
CD68V | ||||||||
0-1 | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
2-4 | 0.42 (0.19-0.91) | 0.027 | 0.46 (0.21-0.99) | 0.049 | 0.41 (0.18-0.92) | 0.032 | 0.45 (0.20-1.01) | 0.054 |
CD66bV | ||||||||
0-1 | 1.00 | - | 1.00 | - | 1.00 | - | 1.00 | - |
2-4 | 0.38 (0.16-0.90) | 0.029 | 0.41 (0.17-0.98) | 0.046 | 0.45 (0.17-1.12) | 0.087 | 0.49 (0.19-1.24) | 0.136 |
Conclusions
Despite having a smaller cohort of tissues, we showed a different expression of immune markers. In particular, CD68-V was associated with a significant positive impact on both OS and PFS. This relation could be partially explained because TAM do not raise only from peripheral blood, but also from resident microglia. Moreover, we observed high density of CD66b+ cells in V related to OS probably for growth factors overproducted by tumor cells with their recruitment from blood. Further studies are needed in large series to explore the prognostic role of selected TME immune molecules to develop therapeutic strategies that aim to hit different components of GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRST and Area Vasta Romagna Ethics Committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10